Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition

11 Feb 2022

Abstract excerpt

Pancreatic cancer is projected to become the second leading cause of cancer-related death by 2030. As patients typically present with advanced disease and show poor responses to broad-spectrum chemotherapy, overall survival remains a dismal 10%. This underscores an urgent clinical need to identify new therapeutic approaches for PDAC patients. Precision medicine is now the standard of care for several...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 35205643
DOI: 10.3390/cancers14040897

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP InhibitionPMID 35205643Read ↗

DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.Semantic proximity Read ↗

DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectivesSemantic proximity Read ↗

BRCA mutations in pancreatic cancer and progress in their targeting.Semantic proximity Read ↗

BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future ProspectsSemantic proximity Read ↗

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applicationsSemantic proximity Read ↗

Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA VariantsSemantic proximity Read ↗

The role of PARP inhibitors in BRCA mutated pancreatic cancerSemantic proximity Read ↗

Targeting DNA Damage Repair Mechanisms in Pancreas CancerSemantic proximity Read ↗

BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment ParadigmsSemantic proximity Read ↗

Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53Semantic proximity Read ↗

Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC.Semantic proximity Read ↗

Targeting BRCA and PALB2 in Pancreatic Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.